Is ALEC or SLDB more profitable?

Solid Biosciences has a net margin of 0.00% compared to Alector's net margin of -850.13%. Solid Biosciences' return on equity of -71.35% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% Solid Biosciences N/A -71.35% -60.58%

Does the media favor ALEC or SLDB?

In the previous week, Solid Biosciences had 1 more articles in the media than Alector. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Alector. Alector's average media sentiment score of 1.27 beat Solid Biosciences' score of 0.91 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, SVRA or ALEC?

Savara has higher earnings, but lower revenue than Alector. Savara is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Alector $21.05M 11.35 -$142.93M -$1.10 N/A

Is SVRA or ALEC more profitable?

Savara has a net margin of 0.00% compared to Alector's net margin of -850.13%. Savara's return on equity of -90.28% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Alector -850.13% -531.03% -44.00%

Does the media refer more to SVRA or ALEC?

In the previous week, Alector had 1 more articles in the media than Savara. MarketBeat recorded 3 mentions for Alector and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Alector's score of 1.27 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CVAC or ALEC?

Alector has a consensus price target of $3.63, indicating a potential upside of 69.39%. Given Alector's stronger consensus rating and higher probable upside, analysts clearly believe Alector is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Which has preferable valuation & earnings, CVAC or ALEC?

CureVac has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Alector $21.05M 11.35 -$142.93M -$1.10 N/A

Is CVAC or ALEC more profitable?

CureVac has a net margin of 199.92% compared to Alector's net margin of -850.13%. CureVac's return on equity of -23.03% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% Alector -850.13% -531.03% -44.00%

Does the media favor AVTX or ALEC?

In the previous week, Avalo Therapeutics had 7 more articles in the media than Alector. MarketBeat recorded 10 mentions for Avalo Therapeutics and 3 mentions for Alector. Alector's average media sentiment score of 1.27 beat Avalo Therapeutics' score of 0.83 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABUS or ALEC more profitable?

Arbutus Biopharma has a net margin of 84.22% compared to Alector's net margin of -850.13%. Arbutus Biopharma's return on equity of 90.98% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 84.22% 90.98% 82.34% Alector -850.13% -531.03% -44.00%

Does the media favor ABUS or ALEC?

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 3 articles in the media. Arbutus Biopharma's average media sentiment score of 1.78 beat Alector's score of 1.27 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alector (ALEC) Competitors

$2.14 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.13 -0.01 (-0.47%)

As of 09/11/2026 07:30 PM Eastern

Compare

ALEC vs. SLDB, SVRA, CVAC, AVTX, and ABUS

Should you buy Alector stock or one of its competitors? Alector's main competitors and comparable companies include Solid Biosciences (SLDB), Savara (SVRA), CureVac (CVAC), Avalo Therapeutics (AVTX), and Arbutus Biopharma (ABUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alector compare to Solid Biosciences?

Alector (NASDAQ:ALEC) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Alector has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	11.35	-$142.93M	-$1.10	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

In the previous week, Solid Biosciences had 1 more articles in the media than Alector. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Alector. Alector's average media sentiment score of 1.27 beat Solid Biosciences' score of 0.91 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alector has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market.

Alector currently has a consensus target price of $3.63, suggesting a potential upside of 69.39%. Solid Biosciences has a consensus target price of $18.18, suggesting a potential upside of 108.99%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

85.8% of Alector shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Solid Biosciences has a net margin of 0.00% compared to Alector's net margin of -850.13%. Solid Biosciences' return on equity of -71.35% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Solid Biosciences	N/A	-71.35%	-60.58%

Summary

Alector beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

How does Alector compare to Savara?

Savara (NASDAQ:SVRA) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Savara has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Alector has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

In the previous week, Alector had 1 more articles in the media than Savara. MarketBeat recorded 3 mentions for Alector and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Alector's score of 1.27 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara presently has a consensus price target of $10.00, indicating a potential upside of 88.68%. Alector has a consensus price target of $3.63, indicating a potential upside of 69.39%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

87.9% of Savara shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Savara has higher earnings, but lower revenue than Alector. Savara is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Alector	$21.05M	11.35	-$142.93M	-$1.10	N/A

Savara has a net margin of 0.00% compared to Alector's net margin of -850.13%. Savara's return on equity of -90.28% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Alector	-850.13%	-531.03%	-44.00%

Summary

Savara beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to CureVac?

CureVac (NASDAQ:CVAC) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Alector's net margin of -850.13%. CureVac's return on equity of -23.03% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Alector	-850.13%	-531.03%	-44.00%

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Alector has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

In the previous week, Alector had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Alector and 0 mentions for CureVac. Alector's average media sentiment score of 1.27 beat CureVac's score of 0.00 indicating that Alector is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Alector	Positive

CureVac has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Alector	$21.05M	11.35	-$142.93M	-$1.10	N/A

Alector has a consensus price target of $3.63, indicating a potential upside of 69.39%. Given Alector's stronger consensus rating and higher probable upside, analysts clearly believe Alector is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

CureVac beats Alector on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Avalo Therapeutics has a net margin of 0.00% compared to Alector's net margin of -850.13%. Avalo Therapeutics' return on equity of -58.03% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Alector	-850.13%	-531.03%	-44.00%

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 179.78%. Alector has a consensus price target of $3.63, indicating a potential upside of 69.39%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Avalo Therapeutics had 7 more articles in the media than Alector. MarketBeat recorded 10 mentions for Avalo Therapeutics and 3 mentions for Alector. Alector's average media sentiment score of 1.27 beat Avalo Therapeutics' score of 0.83 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Alector has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 8.3% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Avalo Therapeutics has higher earnings, but lower revenue than Alector. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	14,408.59	-$78.26M	-$4.37	N/A
Alector	$21.05M	11.35	-$142.93M	-$1.10	N/A

Summary

Avalo Therapeutics beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential downside of 2.34%. Alector has a consensus price target of $3.63, indicating a potential upside of 69.39%. Given Alector's higher probable upside, analysts plainly believe Alector is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Arbutus Biopharma has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	72.04	-$33.50M	$0.79	6.48
Alector	$21.05M	11.35	-$142.93M	-$1.10	N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma has a net margin of 84.22% compared to Alector's net margin of -850.13%. Arbutus Biopharma's return on equity of 90.98% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Alector	-850.13%	-531.03%	-44.00%

Arbutus Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Alector has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 3 articles in the media. Arbutus Biopharma's average media sentiment score of 1.78 beat Alector's score of 1.27 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arbutus Biopharma beats Alector on 10 of the 15 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$238.95M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.72%
P/E Ratio	-1.95	14.18	274.94	25.36
Price / Sales	11.35	1,374.96	685.43	116.38
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	7.64	15.12	10.33	6.20
Net Income	-$142.93M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-13.01%	-4.34%	-3.32%	-2.35%
1 Month Performance	4.90%	0.54%	-0.53%	-3.23%
1 Year Performance	-22.18%	40.74%	23.51%	8.79%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	2.2274 of 5 stars	$2.14 flat	$3.63 +69.4%	-22.2%	$238.95M	$21.05M	N/A	270	Gap Down High Trading Volume
SLDB Solid Biosciences	2.0335 of 5 stars	$10.25 -1.6%	$18.18 +77.4%	+61.4%	$1.12B	N/A	N/A	100	News Coverage Gap Down
SVRA Savara	2.1462 of 5 stars	$5.37 flat	$10.14 +88.9%	+48.9%	$1.10B	N/A	N/A	20	Positive News
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
AVTX Avalo Therapeutics	3.4542 of 5 stars	$19.23 +1.2%	$45.10 +134.5%	+51.4%	$1.02B	$60K	N/A	40	News Coverage Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. SLDB, SVRA, CVAC, AVTX, and ABUS

How does Alector compare to Solid Biosciences?

Summary

How does Alector compare to Savara?

Summary

How does Alector compare to CureVac?

Summary

How does Alector compare to Avalo Therapeutics?

Summary

How does Alector compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. SLDB, SVRA, CVAC, AVTX, and ABUS

How does Alector compare to Solid Biosciences?

Which has better valuation & earnings, ALEC or SLDB?

Does the media favor ALEC or SLDB?

Which has more risk and volatility, ALEC or SLDB?

Do analysts prefer ALEC or SLDB?

Do insiders and institutionals have more ownership in ALEC or SLDB?

Is ALEC or SLDB more profitable?

Summary

How does Alector compare to Savara?

Which has more risk and volatility, SVRA or ALEC?

Does the media refer more to SVRA or ALEC?

Do analysts rate SVRA or ALEC?

Do institutionals and insiders believe in SVRA or ALEC?

Which has preferable valuation and earnings, SVRA or ALEC?

Is SVRA or ALEC more profitable?

Summary

How does Alector compare to CureVac?

Do institutionals and insiders believe in CVAC or ALEC?

Is CVAC or ALEC more profitable?

Which has more volatility and risk, CVAC or ALEC?

Does the media refer more to CVAC or ALEC?

Which has preferable valuation & earnings, CVAC or ALEC?

Do analysts rate CVAC or ALEC?

Summary

How does Alector compare to Avalo Therapeutics?

Is AVTX or ALEC more profitable?

Do analysts rate AVTX or ALEC?

Does the media favor AVTX or ALEC?

Which has more risk & volatility, AVTX or ALEC?

Do insiders and institutionals have more ownership in AVTX or ALEC?

Which has higher valuation and earnings, AVTX or ALEC?

Summary

How does Alector compare to Arbutus Biopharma?

Do analysts prefer ABUS or ALEC?

Which has stronger valuation and earnings, ABUS or ALEC?

Do insiders and institutionals believe in ABUS or ALEC?

Is ABUS or ALEC more profitable?

Which has more volatility & risk, ABUS or ALEC?

Does the media favor ABUS or ALEC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools